Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
| العنوان: | Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade |
|---|---|
| المؤلفون: | Jen Chih Tseng, Li Rung Huang, Chi Ying F. Huang, Tsung-Hsien Chuang, Yu Chen Chuang, Chun Ming Huang |
| المصدر: | Frontiers in Immunology Frontiers in Immunology, Vol 11 (2020) |
| بيانات النشر: | Frontiers Media S.A., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, lcsh:Immunologic diseases. Allergy, medicine.medical_treatment, Immunology, Antineoplastic Agents, Review, CpG-ODN, 03 medical and health sciences, 0302 clinical medicine, Immune system, Cancer immunotherapy, adjuvant, Adjuvants, Immunologic, Neoplasms, medicine, Tumor Microenvironment, Immunology and Allergy, Animals, Humans, Immune Checkpoint Inhibitors, Toll-like receptor, Innate immune system, cancer immunotherapy, business.industry, Immunotherapy, immune checkpoint blockade, Acquired immune system, Blockade, 030104 developmental biology, Oligodeoxyribonucleotides, Toll-Like Receptor 9, Cancer research, toll-like receptor, CpG Islands, innate immune, business, lcsh:RC581-607, Adjuvant, 030215 immunology, Signal Transduction |
| الوصف: | Immunotherapy using checkpoint blockade has revolutionized cancer treatment, improving patient survival and quality of life. Nevertheless, the clinical outcomes of such immunotherapy are highly heterogeneous between patients. Depending on the cancer type, the patient response rates to this immunotherapy are limited to 20-30%. Based on the mechanism underlying the antitumor immune response, new therapeutic strategies have been designed with the aim of increasing the effectiveness and specificity of the antitumor immune response elicited by checkpoint blockade agents. The activation of toll-like receptor 9 (TLR9) by its synthetic agonists induces the antitumor response within the innate immunity arm, generating adjuvant effects and priming the adaptive immune response elicited by checkpoint blockade during the effector phase of tumor-cell killing. This review first describes the underlying mechanisms of action and current status of monotherapy using TLR9 agonists and immune checkpoint inhibitors for cancer immunotherapy. The rationale for combining these two agents is discussed, and evidence indicating the current status of such combination therapy as a novel cancer treatment strategy is presented. |
| اللغة: | English |
| تدمد: | 1664-3224 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec7e585a0e9e2b080ec81e280f833c25Test http://europepmc.org/articles/PMC7274158Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ec7e585a0e9e2b080ec81e280f833c25 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16643224 |
|---|